Biosolution Co Ltd
086820
Company Profile
Business description
Biosolution Co Ltd is a Korean company offering Cell-Based Biotechnology. It is engaged in manufacturing and selling cell therapy products, and developing cell therapeutics technology. Its main areas include cell-based therapeutics with their background in somatic and stem cell technology, and the manufacturing, sales, and R&D of human tissue models for screening toxicity and efficacy with tissue engineering technology.
Contact
Gongneung-Ro 232, Nowon-gu
5th Floor, Room 519, Seoul Technopark
Seoul
KORT: +82 234468884
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
88
Stocks News & Analysis
stocks
Unconventional wisdom: Should I sell this underperforming ASX share?
Going back to my original thesis to evaluate a position.
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,076.60 | 25.40 | -0.28% |
| CAC 40 | 7,743.00 | 33.68 | 0.44% |
| DAX 40 | 24,162.86 | 29.64 | -0.12% |
| Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
| FTSE 100 | 9,095.73 | 5.04 | -0.06% |
| HKSE | 24,858.82 | 222.81 | -0.89% |
| NASDAQ | 21,450.02 | 207.32 | 0.98% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,844.63 | 42.47 | -0.33% |
| S&P 500 | 6,389.45 | 49.45 | 0.78% |
| S&P/ASX 200 | 8,807.10 | 24.30 | -0.28% |
| SSE Composite Index | 3,635.13 | 4.54 | -0.12% |